Similarly, anti-CCR7 mAbs combined with PI3Kδ inhibitors such as Idelalisib (205), a selective inhibitor of the p110 delta isoform, might contribute to inhibition of integrin-mediated arrest of CLL cells on endothelial cells. This evidence concerns the gene CCR7 and B-cell chronic lymphocytic leukemia.